Rakesh K. Jain

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Dai Fukumura · 4 shared papers, 1 shared grant, 2015–2025 · strength 0.95
   • Grant Reengineering obesity-induced abnormal microenvironment to improve PDAC treatment R01CA208205↗
   • Paper IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against… DOI 10.1136/jitc-2024-011404↗
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
2. Yves Boucher · 6 shared papers, 1 shared grant, 2014–2023 · strength 0.83
   • Grant Reprogramming PDAC tumor microenvironment to improve immunotherapy U01CA224348↗
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
3. Mikaël J. Pittet · 2 shared papers, 1 shared grant, 2021–2025 · strength 0.83
   • Grant Reprogramming PDAC tumor microenvironment to improve immunotherapy U01CA224348↗
   • Paper IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against… DOI 10.1136/jitc-2024-011404↗
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
4. Dan Gabriel Duda · 4 shared papers, 2014–2025 · strength 0.48
   • Paper IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against… DOI 10.1136/jitc-2024-011404↗
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
5. Nilesh P. Talele · 3 shared papers, 2019–2025 · strength 0.45
   • Paper IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against… DOI 10.1136/jitc-2024-011404↗
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
6. Theodore Sunki Hong · 4 shared papers, 2014–2023 · strength 0.29
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
   • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
7. David P. Ryan · 4 shared papers, 2014–2023 · strength 0.29
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
   • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
8. Jennifer Yon-Li Wo · 3 shared papers, 2014–2023 · strength 0.24
   • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
   • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
   • Paper A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine f… DOI 10.1016/j.ijrobp.2014.03.034↗
9. Hao Liu · 4 shared papers, 2015–2017 · strength 0.19
   • Paper Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Duct… DOI 10.1016/j.tranon.2016.07.004↗
   • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
   • Paper Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. DOI 10.1371/journal.pone.0141392↗
10. Dig Bijay Mahat · 1 shared paper, 2025 · strength 0.19
    • Paper Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors… DOI 10.1016/j.immuni.2025.06.005↗
11. Phillip A. Sharp · 1 shared paper, 2025 · strength 0.19
    • Paper Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors… DOI 10.1016/j.immuni.2025.06.005↗
12. Carlos F. Fernandez-del Castillo · 2 shared papers, 2014–2023 · strength 0.18
    • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
    • Paper A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine f… DOI 10.1016/j.ijrobp.2014.03.034↗
13. Cristina Rosa Ferrone · 3 shared papers, 2016–2019 · strength 0.15
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
    • Paper Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. DOI 10.1158/2159-8290.cd-15-1177↗
14. Mari A. Mino-Kenudson · 1 shared paper, 2023 · strength 0.14
    • Paper Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Can… DOI 10.1158/1078-0432.ccr-22-1630↗
15. João Incio · 3 shared papers, 2015–2017 · strength 0.14
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
    • Paper Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. DOI 10.1371/journal.pone.0141392↗
    • Paper Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. DOI 10.1158/2159-8290.cd-15-1177↗
16. Vikram Deshpande · 3 shared papers, 2014–2017 · strength 0.13
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
    • Paper Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. DOI 10.1371/journal.pone.0141392↗
    • Paper A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine f… DOI 10.1016/j.ijrobp.2014.03.034↗
17. Janet E. Murphy · 2 shared papers, 2017–2019 · strength 0.11
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
18. Carlos Fernández-del Castillo · 2 shared papers, 2017–2019 · strength 0.11
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
19. Keith D. Lillemoe · 2 shared papers, 2017–2019 · strength 0.11
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
20. Lawrence Scott Blaszkowsky · 2 shared papers, 2014–2019 · strength 0.09
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine f… DOI 10.1016/j.ijrobp.2014.03.034↗
21. Eunice Lee Kwak · 2 shared papers, 2014–2019 · strength 0.09
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
    • Paper A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine f… DOI 10.1016/j.ijrobp.2014.03.034↗
22. Theodoros P. Michelakos · 2 shared papers, 2016–2017 · strength 0.09
    • Paper Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreat… DOI 10.1158/1078-0432.ccr-17-0256↗
    • Paper Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. DOI 10.1158/2159-8290.cd-15-1177↗
23. David Tsai Ting · 1 shared paper, 2019 · strength 0.06
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
24. Jason Edward Faris · 1 shared paper, 2019 · strength 0.06
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗
25. Motaz Qadan · 1 shared paper, 2019 · strength 0.06
    • Paper Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanc… DOI 10.1001/jamaoncol.2019.0892↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.